More on RNTX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $1.19 |
|
|||
| Open | $1.17 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $1.27 | ||||
| Day Low | $1.16 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 77,246 | ||||
- Rein Therapeutics doses first patient in Phase 2 trial for lung disease
- Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
- Form 8-K Rein Therapeutics, Inc. For: Feb 24
- Form 8-K Rein Therapeutics, Inc. For: Feb 16
- Form SCHEDULE 13G/A Rein Therapeutics, Inc. Filed by: Voss Capital, LP
- Jones Trading Starts Rein Therapeutics (RNTX) at Buy
- Brookline Capital Markets Downgrades Rein Therapeutics (RNTX) to Hold
- Rein Therapeutics receives orphan drug designation in Europe for IPF treatment
- Rein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary Fibrosis
- Form 8-K Rein Therapeutics, Inc. For: Jan 15
Entities mentioned with RNTX
- FDA | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- S1 | View Related Stories »
- 13G | View Related Stories »
- H.C. Wainwright | View Related Stories »
- Earnings | View Related Stories »
- Show More...
